

10/519206

Rec'd PCT/PTO 21 DEC 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul S. Keim et al.

Serial No.: tba

Filed: December 21, 2004

For: *A HIGH RESOLUTION TYPING SYSTEM FOR
PATHOGENIC BORRELIA*

Art Unit: tba

Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Dear Sir:

Applicant hereby brings to the attention of the Examiner the documents noted on the accompanying Form PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action.

It is respectfully requested that the information cited herein be expressly considered during the prosecution of this application and made of record on any patent to issue therefrom. Inclusion of a reference on the enclosed 1449 is not to be construed as indicating the reference is prior art. Provision of this Information Disclosure Statement is not to be taken as evidence that a search has been conducted.

The Commissioner is hereby authorized to charge any cost that may be due to Deposit Account No. 17-0055.

Respectfully submitted,
QUARLES & BRADY STREICH LANG, LLP

December 21, 2004

By: Barbara J. Luther
Barbara J. Luther, 33,954

Attorney Docket No. 112624.00082

Address all correspondence to:

Barbara J. Luther

One Renaissance Square
Two North Central Avenue

Phoenix, AZ 85004

Telephone: 602-230-5502

Facsimile: 602-229-5690

Email: bluther@quarles.com

1890012

10/519206

5 Rec'd PCT/PTO 21 DEC 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Paul S. Keim
				Art Unit	tba
				Examiner Name	tba
Sheet	2	of	5	Attorney Docket Number	112624.00082

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	F	ANDERSON, J. F. 1991. Epizootiology of Lyme borreliosis. Scand. J. Infect. Dis. Suppl. 77:23-34.		T ²
	G	BALMELLI, T., 1995. Association between different clinical manifestations of Lyme disease and different species of <i>Borrelia burgdorferi</i> sensu lato. Res. Microbiol. 146:329-340.		
	H	BARBOUR, A. G., 1993. The biological and social phenomenon of Lyme disease. Science 260:1610-1616.		
	I	BELFAIZA, D., 1993 Genomic fingerprinting of <i>Borrelia burgdorferi</i> sensu lato by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31:2873-2877		
	J	BURGDORFER, W., 1991. Relationship of <i>Borrelia burgdorferi</i> to its arthropod vectors. Scand. J. Infect. Dis. Suppl. 77:35-40.		
	K	BUSCH, U., 1996. Three species of <i>Borrelia burgdorferi</i> sensu lato (<i>B. burgdorferi</i> sensu stricto, <i>B. afzelii</i> , and <i>B. garinii</i>) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR. J. Clin. Microbiol. 34:1072-1078.		
	L	CASJENS S., 2000. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete <i>Borrelia burgdorferi</i> . Mol Microbiol. 35:490-516.		
	M	CASJENS S., 1995 Linear chromosomes of Lyme disease agent spirochetes: genetic diversity and conservation of gene order. J. Bacteriol. 177:2769-2780		
	N	CENTERS FOR DISEASE CONTROL AND PREVENTION. Lyme disease-United States, 1997. Morbid. Mortal. Weekly Rep. 46:531-535.		
	O	CENTERS FOR DISEASE CONTROL AND PREVENTION. 1999. Availability of Lyme disease vaccine. Morbid. Mortal. Weekly Rep. 48:35-36, 41.10		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/519206

DT1000's'd PCT/PTO 21 DEC 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	Paul S. Keim
				Art Unit	tba
				Examiner Name	tba
Sheet	3	of	5	Attorney Docket Number	112624.00082

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P	DYKHUIZEN D.E. et al., 2001. The implications of a low rate of horizontal transfer in <i>Borrelia</i> . <i>Trends Microbiol.</i> 9:344-50.	
	Q	DYKHUIZEN D. E. et al., 1993. <i>Borrelia burgdorferi</i> is clonal: implications for taxonomy and vaccine development. <i>Proc. Natl. Acad. Sci. USA</i> 90: 10163-10167.	
	R	EGGERS C.H. et al., 2001. Transduction by phiBB-1, a bacteriophage of <i>Borrelia burgdorferi</i> . <i>J Bacteriol.</i> 183:4771-8	
	S	FARLOW J. et al. <i>Francisella tularensis</i> Strain Typing Using Multiple-Locus, Variable-Number Tandem Repeat Analysis. <i>J Clin Microbiol.</i> 2001 39:3186-92.	
	T	FORTEZ, M., D. et al., 1997 Phylogenetic analysis of <i>Borrelia burgdorferi</i> sensu stricto by arbitrarily primed PCR and pulsed-field gel electrophoresis <i>Int. J. System. Bacteriol.</i> 47:11-18	
	U	FRASER, C. M., et al., 1997. Genomic sequence of a Lyme disease spirochaete, <i>Borrelia burgdorferi</i> . <i>Nature</i> 390:580-586.	
	V	FUKUNAGA, M., et al., 1996. <i>Borrelia tanukii</i> sp. nov. and <i>Borrelia turdae</i> sp. nov. found from ixodid ticks in Japan: rapid species identification by 16S rRNA gene-targeted PCR analysis. <i>Microbiol. Immunol.</i> 40:877-881.	
	W	GERN, L., A. et al., 1998. Euro-pean reservoir hosts of <i>Borrelia burgdorferi</i> sensu lato. <i>Zentbl. Bakteriol.</i> 287:196-204.	
	X	HUBULEK, Z., et al., 1997. Distribution of <i>Borrelia burgdorferi</i> sensu lato genomic groups in Europe, a review. <i>Eur. J. Epidemiol.</i> 13:951- 957.	
	Y	KAWABATA, H., et al., 1993. Genomic analysis of <i>Borrelia japonica</i> sp. nov. isolated from <i>Ixodes ovatus</i> in Japan. <i>Microbiol. Immunol.</i> 37:841-848.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/519206

Rec'd PCT/PTO 21 DEC 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	4	of	5	Attorney Docket Number	112624.00082

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	Z	KEIM P. et al., 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within <i>Bacillus anthracis</i> . <i>J Bacteriol</i> May; 182:2928-36.			
	AA	MARCONI, R. T., et al., 1995. Identification of novel insertion elements, restriction fragment length polymorphism patterns, and discontinuous 23S rRNA in Lyme disease spirochetes: phylogenetic analyses of rRNA genes and their intergenic spacers in			
	AB	MARTI Ras., et al., 1997 <i>Borelia burgdorferi</i> sensu stricto, a bacterial species "made in the USA"? <i>Int. J. System. Bacteriol.</i> 47: 1112-1117			
	AC	MURRAY, P.R., et al., 1999. <i>Manual of Clinical Microbiology</i> . 7th edition. ASM Press, Washington D.C.			
	AD	NADELMAN, R. B., et al., 1998. <i>Lyme borreliosis</i> . <i>Lancet</i> 352:557-565.			
	AE	NICHOLLS, T. H., et al., 1996. <i>Lyme disease spirochetes in ticks collected from birds in mid-western United States</i> . <i>J. Med. Entomol.</i> 33:379-384.			
	AF	OHLENBUSCH, A., et al., 1996. <i>Etiology of the acrodermatitis chronica atrophicans</i> lesion in <i>Lyme disease</i> . <i>J. Infect. Dis.</i> 174:421-423.			
	AG	PETER, O., et al., 1997. <i>Association of distinct species of <i>Borrelia burgdorferi</i> sensu lato with neuroborreliosis in Switzerland</i> . <i>Clin. Microbiol. Infect.</i> 3:423-411.			
	AH	PICKEN, R. N., et al., 1998. <i>Identification of three species of <i>Borrelia burgdorferi</i> sensu lato (B. burgdorferi sensu stricto, B. garinii, and B. afzelii) among isolates from acrodermatitis chronica atrophicans lesions</i> . <i>J. Investig. Dermatol.</i> 110:211-214.			
	AI	POSTIC D., et al., 1999 <i>Common ancestry of <i>Borrelia burgdorferi</i> sensu lato strains from North America and Europe</i> . <i>J. Clin. Microbiol.</i> 37:3010-3012			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/519206

5 Rec'd PCT/PTO 21 DEC 2004

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	5	of	5	Attorney Docket Number	112624.00082

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AJ	POSTIC, D., et al., 1998. Expanded Diversity among California Borrelia isolates and description of Borrelia bissettii sp. nov. (formerly Borrelia group DN127). J. Clin. Microbiol. 36:3497-3504			
	AK	SCHMID, G. P. 1985. The global distribution of Lyme disease. Rev. Infect. Dis. 7:41-50.			
	AL	WANG, G., et al., 1999. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical Implications. Clin. Micr. Rev. 12:633-653.			
	AM	WEIR, B.S. 1990. Genetic Data Anlysis. Sinauer Associates, Inc. Sunderland, MA. USA.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.